

## PATENT COOPERATION TREATY

PCT

## NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Commissioner  
 US Department of Commerce  
 United States Patent and Trademark  
 Office, PCT  
 2011 South Clark Place Room  
 CP2/5C24  
 Arlington, VA 22202  
 ETATS-UNIS D'AMERIQUE  
 in its capacity as elected Office

<b>Date of mailing</b> (day/month/year) 01 December 2000 (01.12.00)	
<b>International application No.</b> PCT/SE00/00878	<b>Applicant's or agent's file reference</b> H 2174-1 WO
<b>International filing date</b> (day/month/year) 04 May 2000 (04.05.00)	<b>Priority date</b> (day/month/year) 06 May 1999 (06.05.99)
<b>Applicant</b> EKSTRAND, Jonas et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:  
 30 October 2000 (30.10.00)

☐ in a notice effecting later election filed with the International Bureau on:  
 \_\_\_\_\_

2. The election ☒ was

☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer Charlotte ENGER Telephone No.: (41-22) 338.83.38
---	---

PTO/PO

AUG 2000

PCT

For receiving Office use only

## REQUEST

The undersigned requests that the present international application be processed according to the Patent Cooperation Treaty.

International Application No.

International Filing Date

Name of receiving Office and "PCT International Application"

Applicant's or agent's file reference  
(if desired) (12 characters maximum) H 2174-1 WO

## Box No. I TITLE OF INVENTION

NEW METHODS

## Box No. II APPLICANT

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

AstraZeneca AB  
S-151 85 Södertälje  
Sweden

☐ This person is also inventor.

Telephone No.

+46 8 553 260 00

Facsimile No.

+46 8 553 288 20

Teleprinter No.

State (that is, country) of nationality:

SE

State (that is, country) of residence:

SE

This person is applicant  
for the purposes of:

☐ all designated  
States☒ all designated States except  
the United States of America☐ the United States  
of America only☐ the States indicated in  
the Supplemental Box

## Box No. III FURTHER APPLICANT(S) AND/OR (FURTHER) INVENTOR(S)

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

EKSTRAND, Jonas  
AstraZeneca R&D Umeå  
Tvistevägen 48  
S-907 36 Umeå  
Sweden

This person is:

☐ applicant only☒ applicant and inventor☐ inventor only (If this check-box  
is marked, do not fill in below.)

State (that is, country) of nationality:

State (that is, country) of residence:

This person is applicant  
for the purposes of:

☐ all designated  
States☐ all designated States except  
the United States of America☒ the United States  
of America only☐ the States indicated in  
the Supplemental Box☒ Further applicants and/or (further) inventors are indicated on a continuation sheet.

## Box No. IV AGENT OR COMMON REPRESENTATIVE; OR ADDRESS FOR CORRESPONDENCE

The person identified below is hereby/has been appointed to act on behalf  
of the applicant(s) before the competent International Authorities as:

☒ agent☐ common representative

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country.)

Global Intellectual Property, Patents  
AstraZeneca AB  
S-151 85 Södertälje  
Sweden

Telephone No.

+46 8 553 260 00

Facsimile No.

+46 8 553 288 20

Teleprinter No.

☐ Address for correspondence: Mark this check-box where no agent or common representative is/has been appointed and the space above is used instead to indicate a special address to which correspondence should be sent.

## Continuation of Box No. III FURTHER APPLICANT(S) AND/OR (FURTHER) INVENTOR(S)

If none of the following sub-boxes is used, this sheet should not be included in the request.

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

EDLUND, Anders  
AstraZeneca R&D Umeå  
Tvistevägen 48  
S-907 36 Umeå  
Sweden

This person is:

- ☐ applicant only  
☒ applicant and inventor  
☐ inventor only (If this check-box is marked, do not fill in below.)

State (that is, country) of nationality:  
SE

State (that is, country) of residence:  
SE

This person is applicant for the purposes of:

☐ all designated States

☐ all designated States except the United States of America

☒ the United States of America only

☐ the States indicated in the Supplemental Box

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

JOHANSSON, Thore  
AstraZeneca R&D Umeå  
Tvistevägen 48  
S-907 36 Umeå  
Sweden

This person is:

- ☐ applicant only  
☒ applicant and inventor  
☐ inventor only (If this check-box is marked, do not fill in below.)

State (that is, country) of nationality:  
SE

State (that is, country) of residence:  
SE

This person is applicant for the purposes of:

☐ all designated States

☐ all designated States except the United States of America

☐ the United States of America only

☐ the States indicated in the Supplemental Box

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

LEONARDSSON, Göran  
AstraZeneca R&D Mölndal  
S-431 83 Mölndal  
Sweden

This person is:

- ☐ applicant only  
☒ applicant and inventor  
☐ inventor only (If this check-box is marked, do not fill in below.)

State (that is, country) of nationality:  
SE

State (that is, country) of residence:  
SE

This person is applicant for the purposes of:

☐ all designated States

☐ all designated States except the United States of America

☒ the United States of America only

☐ the States indicated in the Supplemental Box

Name and address: (Family name followed by given name; for a legal entity, full official designation. The address must include postal code and name of country. The country of the address indicated in this Box is the applicant's State (that is, country) of residence if no State of residence is indicated below.)

This person is:

- ☐ applicant only  
☐ applicant and inventor  
☐ inventor only (If this check-box is marked, do not fill in below.)

State (that is, country) of nationality:

State (that is, country) of residence:

This person is applicant for the purposes of:

☐ all designated States

☐ all designated States except the United States of America

☐ the United States of America only

☐ the States indicated in the Supplemental Box

☐ Further applicants and/or (further) inventors are indicated on another continuation sheet.

**Box No. V DESIGNATION OF STATES**

The following designations are hereby made under Rule 4.9(a) (mark the applicable check-boxes; at least one must be marked):

**Regional Patent**

- ☒ **AP ARIPO Patent:** GH Ghana, GM Gambia, KE Kenya, LS Lesotho, MW Malawi, SD Sudan, SL Sierra Leone, SZ Swaziland, TZ United Republic of Tanzania, UG Uganda, ZW Zimbabwe, and any other State which is a Contracting State of the Harare Protocol and of the PCT
- ☒ **EA Eurasian Patent:** AM Armenia, AZ Azerbaijan, BY Belarus, KG Kyrgyzstan, KZ Kazakhstan, MD Republic of Moldova, RU Russian Federation, TJ Tajikistan, TM Turkmenistan, and any other State which is a Contracting State of the Eurasian Patent Convention and of the PCT
- ☒ **EP European Patent:** AT Austria, BE Belgium, CH and LI Switzerland and Liechtenstein, CY Cyprus, DE Germany, DK Denmark, ES Spain, FI Finland, FR France, GB United Kingdom, GR Greece, IE Ireland, IT Italy, LU Luxembourg, MC Monaco, NL Netherlands, PT Portugal, SE Sweden, and any other State which is a Contracting State of the European Patent Convention and of the PCT
- ☒ **OA OAPI Patent:** BF Burkina Faso, BJ Benin, CF Central African Republic, CG Congo, CI Côte d'Ivoire, CM Cameroon, GA Gabon, GN Guinea, GW Guinea-Bissau, ML Mali, MR Mauritania, NE Niger, SN Senegal, TD Chad, TG Togo, and any other State which is a member State of OAPI and a Contracting State of the PCT (if other kind of protection or treatment desired, specify on dotted line)

**National Patent (if other kind of protection or treatment desired, specify on dotted line):**

- |   |  |
|---|--|
| <input checked="" type="checkbox"/> <b>AE</b> United Arab Emirates                  | <input checked="" type="checkbox"/> <b>LR</b> Liberia  |
| <input checked="" type="checkbox"/> <b>AL</b> Albania                               | <input checked="" type="checkbox"/> <b>LS</b> Lesotho  |
| <input checked="" type="checkbox"/> <b>AM</b> Armenia                               | <input checked="" type="checkbox"/> <b>LT</b> Lithuania  |
| <input checked="" type="checkbox"/> <b>AT</b> Austria                               | <input checked="" type="checkbox"/> <b>LU</b> Luxembourg   |
| <input checked="" type="checkbox"/> <b>AU</b> Australia                             | <input checked="" type="checkbox"/> <b>LV</b> Latvia   |
| <input checked="" type="checkbox"/> <b>AZ</b> Azerbaijan                            | <input checked="" type="checkbox"/> <b>MA</b> Morocco  |
| <input checked="" type="checkbox"/> <b>BA</b> Bosnia and Herzegovina                | <input checked="" type="checkbox"/> <b>MD</b> Republic of Moldova  |
| <input checked="" type="checkbox"/> <b>BB</b> Barbados                              | <input checked="" type="checkbox"/> <b>MG</b> Madagascar   |
| <input checked="" type="checkbox"/> <b>BG</b> Bulgaria                              | <input checked="" type="checkbox"/> <b>MK</b> The former Yugoslav Republic of Macedonia                      |
| <input checked="" type="checkbox"/> <b>BR</b> Brazil                                | <input checked="" type="checkbox"/> <b>MN</b> Mongolia   |
| <input checked="" type="checkbox"/> <b>BY</b> Belarus                               | <input checked="" type="checkbox"/> <b>MW</b> Malawi   |
| <input checked="" type="checkbox"/> <b>CA</b> Canada                                | <input checked="" type="checkbox"/> <b>MX</b> Mexico   |
| <input checked="" type="checkbox"/> <b>CH and LI</b> Switzerland and Liechtenstein  | <input checked="" type="checkbox"/> <b>NO</b> Norway   |
| <input checked="" type="checkbox"/> <b>CN</b> China                                 | <input checked="" type="checkbox"/> <b>NZ</b> New Zealand  |
| <input checked="" type="checkbox"/> <b>CR</b> Costa Rica                            | <input checked="" type="checkbox"/> <b>PL</b> Poland   |
| <input checked="" type="checkbox"/> <b>CU</b> Cuba                                  | <input checked="" type="checkbox"/> <b>PT</b> Portugal   |
| <input checked="" type="checkbox"/> <b>CZ</b> Czech Republic                        | <input checked="" type="checkbox"/> <b>RO</b> Romania  |
| <input checked="" type="checkbox"/> <b>DE</b> Germany                               | <input checked="" type="checkbox"/> <b>RU</b> Russian Federation   |
| <input checked="" type="checkbox"/> <b>DK</b> Denmark                               | <input checked="" type="checkbox"/> <b>SD</b> Sudan  |
| <input checked="" type="checkbox"/> <b>DM</b> Dominica                              | <input checked="" type="checkbox"/> <b>SE</b> Sweden   |
| <input checked="" type="checkbox"/> <b>EE</b> Estonia                               | <input checked="" type="checkbox"/> <b>SG</b> Singapore  |
| <input checked="" type="checkbox"/> <b>ES</b> Spain                                 | <input checked="" type="checkbox"/> <b>SI</b> Slovenia   |
| <input checked="" type="checkbox"/> <b>FI</b> Finland                               | <input checked="" type="checkbox"/> <b>SK</b> Slovakia   |
| <input checked="" type="checkbox"/> <b>GB</b> United Kingdom                        | <input checked="" type="checkbox"/> <b>SL</b> Sierra Leone   |
| <input checked="" type="checkbox"/> <b>GD</b> Grenada                               | <input checked="" type="checkbox"/> <b>TJ</b> Tajikistan   |
| <input checked="" type="checkbox"/> <b>GE</b> Georgia                               | <input checked="" type="checkbox"/> <b>TM</b> Turkmenistan   |
| <input checked="" type="checkbox"/> <b>GH</b> Ghana                                 | <input checked="" type="checkbox"/> <b>TR</b> Turkey   |
| <input checked="" type="checkbox"/> <b>GM</b> Gambia                                | <input checked="" type="checkbox"/> <b>TT</b> Trinidad and Tobago  |
| <input checked="" type="checkbox"/> <b>HR</b> Croatia                               | <input checked="" type="checkbox"/> <b>TZ</b> United Republic of Tanzania                                    |
| <input checked="" type="checkbox"/> <b>HU</b> Hungary                               | <input checked="" type="checkbox"/> <b>UA</b> Ukraine  |
| <input checked="" type="checkbox"/> <b>ID</b> Indonesia                             | <input checked="" type="checkbox"/> <b>UG</b> Uganda   |
| <input checked="" type="checkbox"/> <b>IL</b> Israel                                | <input checked="" type="checkbox"/> <b>US</b> United States of America                                       |
| <input checked="" type="checkbox"/> <b>IN</b> India                                 |  |
| <input checked="" type="checkbox"/> <b>IS</b> Iceland                               |  |
| <input checked="" type="checkbox"/> <b>JP</b> Japan                                 | <input checked="" type="checkbox"/> <b>UZ</b> Uzbekistan   |
| <input checked="" type="checkbox"/> <b>KE</b> Kenya                                 | <input checked="" type="checkbox"/> <b>VN</b> Viet Nam   |
| <input checked="" type="checkbox"/> <b>KG</b> Kyrgyzstan                            | <input checked="" type="checkbox"/> <b>YU</b> Yugoslavia   |
| <input checked="" type="checkbox"/> <b>KP</b> Democratic People's Republic of Korea | <input checked="" type="checkbox"/> <b>ZA</b> South Africa   |
|   | <input checked="" type="checkbox"/> <b>ZW</b> Zimbabwe   |
| <input checked="" type="checkbox"/> <b>KR</b> Republic of Korea                     | Check-boxes reserved for designating States which have become party to the PCT after issuance of this sheet: |
| <input checked="" type="checkbox"/> <b>KZ</b> Kazakhstan                            | <input checked="" type="checkbox"/> <b>DZ</b> Algeria  |
| <input checked="" type="checkbox"/> <b>LC</b> Saint Lucia                           | <input checked="" type="checkbox"/> <b>AG</b> Antigua and Barbuda  |
| <input checked="" type="checkbox"/> <b>LK</b> Sri Lanka                             |  |

**Precautionary Designation Statement:** In addition to the designations made above, the applicant also makes under Rule 4.9(b) all other designations which would be permitted under the PCT except any designation(s) indicated in the Supplemental Box as being excluded from the scope of this statement. The applicant declares that those additional designations are subject to confirmation and that any designation which is not confirmed before the expiration of 15 months from the priority date is to be regarded as withdrawn by the applicant at the expiration of that time limit. (Confirmation (including fees) must reach the receiving Office within the 15-month time limit.)


<b>Box No. VI PRIORITY CLAIM</b>					<input type="checkbox"/> Further priority claims are indicated in the Supplemental Box.
Filing date of earlier application (day/month/year)	Number of earlier application	Where earlier application is:			
		national application: country	regional application: * regional Office	international application: receiving Office	
item (1) 06 May 1999 (06.05.1999)	9901659-4	Sweden (SE)			
item (2)					
item (3)					

☒ The receiving Office is requested to prepare and transmit to the International Bureau a certified copy of the earlier application(s) (only if the earlier application was filed with the Office which for the purposes of the present international application is the receiving Office) identified above as item(s): (1)

\* Where the earlier application is an ARIPO application, it is mandatory to indicate in the Supplemental Box at least one country party to the Paris Convention for the Protection of Industrial Property for which that earlier application was filed (Rule 4.10(b)(ii)). See Supplemental Box.

<b>Box No. VII INTERNATIONAL SEARCHING AUTHORITY</b>			
<b>Choice of International Searching Authority (ISA)</b> (if two or more International Searching Authorities are competent to carry out the international search, indicate the Authority chosen; the two-letter code may be used):		<b>Request to use results of earlier search; reference to that search</b> (if an earlier search has been carried out by or requested from the International Searching Authority):	
ISA/ SE		Date (day/month/year) 27 December 1999	Number SE99/00556
		Country (or regional Office) Sweden (SE)	

<b>Box No. VIII CHECK LIST; LANGUAGE OF FILING</b>	
This international application contains the following number of sheets: request : 4 description (excluding sequence listing part) : 26 claims : 5 abstract : 1 drawings : 6 sequence listing part of description : 4 Total number of sheets : 46	This international application is accompanied by the item(s) marked below: 1. <input checked="" type="checkbox"/> fee calculation sheet 2. <input type="checkbox"/> separate signed power of attorney 3. <input checked="" type="checkbox"/> copy of general power of attorney, reference number, if any: GF1189/2000 4. <input type="checkbox"/> statement explaining lack of signature 5. <input type="checkbox"/> priority document(s) identified in Box No. VI as item(s): 6. <input type="checkbox"/> translation of international application into (language): 7. <input type="checkbox"/> separate indications concerning deposited microorganism or other biological material 8. <input checked="" type="checkbox"/> nucleotide and/or amino acid sequence listing in computer readable form 9. <input checked="" type="checkbox"/> other (specify): ITS Report SE99/00556
Figure of the drawings which should accompany the abstract: 1	Language of filing of the international application: English

<b>Box No. IX SIGNATURE OF APPLICANT OR AGENT</b>	
<i>Next to each signature, indicate the name of the person signing and the capacity in which the person signs (if such capacity is not obvious from reading the request).</i>	
Södertälje, 4 May 2000	
	
Sten Danielsson	
Global Intellectual Property, Patents, AstraZeneca AB	

For receiving Office use only	
1. Date of actual receipt of the purported international application: 3. Corrected date of actual receipt due to later but timely received papers or drawings completing the purported international application: 4. Date of timely receipt of the required corrections under PCT Article 11(2): 5. International Searching Authority (if two or more are competent): ISA /	2. Drawings: <input type="checkbox"/> received: <input type="checkbox"/> not received: 6. <input type="checkbox"/> Transmittal of search copy delayed until search fee is paid.

For International Bureau use only
Date of receipt of the record copy by the International Bureau:

09/622745

## PATENT COOPERATION TREATY

## PCT

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

REC'D 13 SEP 2001

TECHNICAL CENTER 1600/200  
NOV 29 2001

RECEIVED

14

Applicant's or agent's file reference H 2174-1 WO	<b>FOR FURTHER ACTION</b> See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/SE00/00878	International filing date (day/month/year) 04.05.2000	Priority date (day/month/year) 06.05.1999
International Patent Classification (IPC) or national classification and IPC <sub>7</sub> C 07 K 14/705, A 01 K 67/027		
Applicant AstraZeneca AB et al		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of 4 sheets, including this cover sheet.

☐ This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of \_\_\_\_\_ sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☐ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☐ Certain observations on the international application

Date of submission of the demand  30.10.2000	Date of completion of this report  06.09.2001
Name and mailing address of the IPEA/SE Patent- och registreringsverket Box 5055 S-102 42 STOCKHOLM Facsimile No. 08-667 72 88	Authorized officer  Hampus Rystedt/EÖ Telephone No. 08-782 25 00

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/SE00/00878

**I. Basis of the report****1. With regard to the elements of the international application:\***

- ☒ the international application as originally filed
- ☐ the description:  
pages \_\_\_\_\_, as originally filed  
pages \_\_\_\_\_, filed with the demand  
pages \_\_\_\_\_, filed with the letter of \_\_\_\_\_
- ☐ the claims:  
pages \_\_\_\_\_, as originally filed  
pages \_\_\_\_\_, as amended (together with any statement) under article 19  
pages \_\_\_\_\_, filed with the demand  
pages \_\_\_\_\_, filed with the letter of \_\_\_\_\_
- ☐ the drawings:  
pages \_\_\_\_\_, as originally filed  
pages \_\_\_\_\_, filed with the demand  
pages \_\_\_\_\_, filed with the letter of \_\_\_\_\_
- ☐ the sequence listing part of the description:  
pages \_\_\_\_\_, as originally filed  
pages \_\_\_\_\_, filed with the demand  
pages \_\_\_\_\_, filed with the letter of \_\_\_\_\_

**2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.**

These elements were available or furnished to this Authority in the following language \_\_\_\_\_ which is:

- ☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

**3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:**

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

**4. ☐ The amendments have resulted in the cancellation of:**

- ☐ the description, pages \_\_\_\_\_
- ☐ the claims, Nos. \_\_\_\_\_
- ☐ the drawings, sheet/fig \_\_\_\_\_

**5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2 (c)).\*\***

\* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

\*\* Any replacement sheet containing such amendments must be referred to under item I and annexed to this report.

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/SE00/00878

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement****1. Statement**

Novelty (N)	Claims	<u>1-31</u>	YES
	Claims		NO
Inventive step (IS)	Claims		YES
	Claims	<u>1-31</u>	NO
Industrial applicability (IA)	Claims	<u>1-31</u>	YES
	Claims		NO

**2. Citations and explanations (Rule 70.7)**

The claimed invention relates to nucleic acid molecules constituting a human GABAb receptor 1 promoter. Further, the application relates to subjects related to molecules such as vectors, host cells, expression systems and assays.

D1) Younger R. GeneBank accession no AL031983

D2) Peters HC et al., " Mapping, genomic structure, and polymorphism of the human GABAbR1 receptor gene: evaluation of its involvement in idiopathic generalized epilepsy", 1998, vol 2, pages 47-54

D3) WO97/466575, A1

D1 discloses the sequence of the chromosome loci encoding inter alia the GABAb receptor. D1 identifies two putative CpG islands in the region encoding the GABA receptor; CpG- islands are GC rich regions indicating transcription initiation e.g. for spliced variants. The CG-rich regions of D1 correspond to the promoters claimed (position bp 4520-5633( bp 2914-4027 of SEQ NO 1 according to numbering in the present application) and 9500-10376(bp 3985-4361 of SEQ NO 2 according to numbering in the present application).

D2 discloses the genomic structure of the human GABAbR1 receptor gene. D2 finds that the intron region between exons 1a4 and 1a (as defined in D2) probably contain the promoters for the GABAb R1b receptor. This region seems to correspond to the region above exon 6 (as defined in the present application) i.e. promoter P1b. Moreover, an additional exon is postulated above exon 1a1, refer to page 52 column 2, lines 45-56. In D2, polymorphism in the GABAb- receptor is studied in patients suffering from epilepsy. Polymorphisms in the regulatory region is said to be of interest.

.../...



INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/SE00/00878

**Supplemental Box**

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: V

How to find the promoter region of a known gene is considered to be obvious to a person skilled in the art unless an unexpected special technical problem is solved. In the present case, the information in D1 or D2 narrows the region of where to search; the cloning of the promoters is facilitated further. Thus, the invention according to claims 1-21 is novel has industrial applicability, but is considered to lack an inventive step.

D3 discloses a transgenic animal with a modulated expression of a GABAb receptor as well as a test system for identification of compounds effecting the expression of GABAb receptors, refer to page 19, lines 1-5 and claim 11. The control sequences used are not defined, however it seems obvious to a person skilled in the art that a promoter sequence may be used as a control sequence in the method of D3. Thus, the invention according to claims 21-31 is considered obvious to a person skilled in the art.

The invention according to claims 21-31 is novel, industrially applicable, but not considered to involve an inventive step.

09622745  
500

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>C07K 14/705, A01K 67/027</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/68268</b> <b>(43) International Publication Date:</b> 16 November 2000 (16.11.00)
<b>(21) International Application Number:</b> PCT/SE00/00878 <b>(22) International Filing Date:</b> 4 May 2000 (04.05.00) <b>(30) Priority Data:</b> 9901659-4 6 May 1999 (06.05.99) SE <b>(71) Applicant (for all designated States except US):</b> AS-TRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> EKSTRAND, Jonas [SE/SE]; AstraZeneca R & D Umeå, Tvistevägen 48, S-907 36 Umeå (SE). EDLUND, Anders [SE/SE]; AstraZeneca R & D Umeå, Tvistevägen 48, S-907 36 Umeå (SE). JOHANSSON, Thore [SE/SE]; AstraZeneca R & D Umeå, Tvistevägen 48, S-907 36 Umeå (SE). LEONARDSSON, Göran [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). <b>(74) Agent:</b> ASTRAZENECA AB; Global Intellectual Property, Patents, S-151 85 Södertälje (SE).		<b>(81) Designated States:</b> AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> HUMAN GABA <sub>B</sub> RECEPTOR 1 PROMOTERS  <b>(57) Abstract</b>  The present invention relates to nucleic acid molecules constituting GABA <sub>B</sub> receptor 1 promoters P1a and/or P1b, and to methods for screening for compounds which are modulators of GABA <sub>B</sub> receptor 1 transcription, said methods comprising the use of nucleic acid molecules constituting GABA <sub>B</sub> receptor P1a and/or P1b promoters.		

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

HUMAN GABA<sub>B</sub> RECEPTOR 1 PROMOTERS

## FIELD OF THE INVENTION

5 The present invention relates to nucleic acid molecules constituting GABA<sub>B</sub> receptor 1 promoters P1a and/or P1b, and to methods for screening for compounds which are modulators of GABA<sub>B</sub> receptor 1 transcription, said methods comprising the use of nucleic acid molecules constituting GABA<sub>B</sub> receptor P1a and/or P1b promoters.

## 10 BACKGROUND

*GABA<sub>B</sub> receptor 1*

GABA ( $\gamma$ -aminobutyric acid) is an endogenous neurotransmitter in the central and peripheral nervous systems. Receptors for GABA have traditionally been divided into GABA<sub>A</sub> and GABA<sub>B</sub> receptor subtypes. GABA<sub>B</sub> receptors (for a review see Kerr, D.I.B. and Ong, J. (1995) Pharmac. Ther. vol. 67, pp.187-246) belong to the superfamily of G-protein coupled receptors. GABA<sub>B</sub> receptor agonists are described as being of use in the treatment of CNS disorders, such as muscle relaxation in spinal spasticity, cardiovascular disorders, asthma, gut motility disorders such as irritable bowel syndrome and as prokinetic and anti-tussive agents. GABA<sub>B</sub> receptor agonists have also been disclosed as useful in the treatment of emesis (WO 96/11680) and reflux disease (WO 98/11885).

The cloning of the cDNA encoding the rat GABA<sub>B</sub> receptors splice isoforms GABA<sub>B</sub>R1a and GABA<sub>B</sub>R1b is disclosed by Kaupmann et al. (1997) Nature, vol. 386, 239-246. The mature rat GABA<sub>B</sub>R1b differed from GABA<sub>B</sub>R1a in that the N-terminal 147 residues were replaced by 18 different residues. It was presumed that the rat GABA<sub>B</sub>R1a and -b receptor variants are derived from the same gene by alternative splicing.

The cloning of the cDNA encoding the human GABA<sub>B</sub> receptor GABA<sub>B</sub>R1b is disclosed in WO 97/46675.

The cloning of the human GABA<sub>B</sub> receptor 1 gene and the elucidation of the exon-intron organization is in part or fully disclosed in PCT/SE98/01947, in EMBL HS271M21 (GenBank AL031983), EMBL AJ010170 to AJ010191, in Peters, HC et al., *Neurogenetics* 2; 47-54 (1998) and in Goei, VL et al. *Biological Psychiatry*, 44: 659-66 (1998). The human GABA<sub>B</sub> receptor 1 gene consists of 23 exons, spanning over a distance of 30 kb (Figure 1). The elucidation of the gene organization revealed that the human GABA<sub>B</sub>R1a and GABA<sub>B</sub>R1b are splice variants encoded by a single gene. The GABA<sub>B</sub>R1a and GABA<sub>B</sub>R1b isoforms are differentially expressed, at least in the rat (Kaupmann et al. (1997) *Nature*, vol. 386, 239-246). The physiological consequences of multiple GABA<sub>B</sub> receptor 1 splice isoforms has not yet been determined, but their existence constitute an opportunity for the development of specific pharmaceutical agents.

#### *GABA<sub>B</sub> receptor 2*

Based on its homology with the mammalian GABA<sub>B</sub>R1 cDNA, a second member of the GABA<sub>B</sub> receptor family was identified (Jones, KA et al., *Nature* 396; 674-679 (1998), White, JA et al., *Nature* 396; 679-682 (1998), Kaupmann, K et al., *Nature* 396; 683-687 (1998), WO 99/20751). The corresponding protein, GABA<sub>B</sub>R2, forms heteromers with GABA<sub>B</sub>R1a and R1b, resulting in cell surface expression of a functional GABA<sub>B</sub> receptor (Kuner, R et al. *Science* 283, 74-77 (1999)). At least in recombinant expression systems, GABA<sub>B</sub>R1 and R2 coexpression is necessary for the formation of a functional GABA<sub>B</sub> receptor. Jones et al. (*Nature* 396; 674-679 (1998)) disclosed that a GABA<sub>B</sub>R1: GABA<sub>B</sub>R2 stoichiometry of 1:1 is an optimal ratio for successful cell surface expression of a ligand binding and functional GABA<sub>B</sub> receptor. Thus, modulating GABA<sub>B</sub>R1 expression could alter the stoichiometry between GABA<sub>B</sub>R1 and other interacting proteins and be a means to regulate signaling through GABA<sub>B</sub> receptors and thereby interfere with various physiological processes.

#### *Transcriptional regulation*

Gene regulation is mediated by specific DNA elements in the promoter that directs binding of transcription factors, which thereby mediate transcription of the gene. Eukaryotic transcription factors can be divided in two main groups i) basal transcription factors that

interact with promoter sequences proximal to the start of transcription, thereby initiating transcription upon recruitment of RNA polymerase II and *ii*) transcription factors that bind to specific distal promoter elements, thereby modulating the transcription upon contact with the basal transcription machinery. The DNA sequence that directs the start of transcription in most eukaryotic genes is the TATA-box, which is often located approximately 30 base pairs upstream from the start of transcription. However, the TATA-box is not a prerequisite for initiation of transcription as there are many promoters, including the GABA<sub>B</sub> R1 promoters described in this study, that lack a TATA-box. A fundamental physiological process in the eukaryotic organism is that cells can communicate with their environment and respond to extracellular stimuli through signaling molecules, such as hormones and growth factors. The final event for such signaling is the binding of transcription factors to specific distal promoter elements leading to for example up-regulated or tissue specific gene expression. Because of their regulatory role, signaling molecules are putative targets for screening of therapeutic agents. The presence of two distinct and differentially regulated promoters within the human GABA<sub>B</sub> receptor 1 gene, disclosed in this patent application, makes it possible to screen for therapeutic agents selectively regulating expression of GABA<sub>B</sub> receptor 1a and 1b-type splice isoforms.

### *Indications*

Compounds which are modulators of GABA<sub>B</sub> receptor 1 transcription are potentially useful in the treatment of disorders which are related to neurally-controlled physiological responses regulated by GABA<sub>B</sub> receptors, e.g. CNS disorders such as muscle relaxation in spinal spasticity, Alzheimer's disease and other dementias, psychiatric and neurological disorders such as depression, anxiety and epilepsy, cardiovascular disorders, asthma, gut motility disorders such as irritable bowel syndrome, emesis and reflux disease.

In some humans, the lower esophageal sphincter (LES) is prone to relaxing more frequently than in other humans. As a consequence, fluid from the stomach can pass into the esophagus since the mechanical barrier is temporarily lost at such times, an event hereinafter referred to as "reflux".

Gastro-esophageal reflux disease (GERD) is the most prevalent upper gastrointestinal tract disease. Current therapy has aimed at reducing gastric acid secretion, or by reducing esophageal acid exposure by enhancing esophageal clearance, lower esophageal sphincter tone and gastric emptying. The major mechanism behind reflux has been considered to depend on a hypotonic lower esophageal sphincter. However, recent research (e.g. Holloway & Dent (1990) *Gastroenterol. Clin. N. Amer.* 19, 517-535) has shown that most reflux episodes occur during transient lower esophageal sphincter relaxations (TLESR), i.e. relaxations not triggered by swallows. It has also been shown that gastric acid secretion usually is normal in patients with GERD. Consequently, there is a need for compounds which reduce the incidence of TLESR and thereby prevent reflux.

#### DESCRIPTION OF THE INVENTION

15

This invention relates to nucleic acid molecules constituting GABA<sub>B</sub> receptor 1 promoters and fragments of said promoters. By GABA<sub>B</sub> receptor 1 promoters is understood the nucleic acids sequences upstream of the ATG translation initiation codon of GABA<sub>B</sub> receptor 1a of the GABA<sub>B</sub> receptor 1 gene, designated P1a, and the nucleic acids sequences upstream of the ATG translation initiation codon of GABA<sub>B</sub> receptor 1b of the GABA<sub>B</sub> receptor 1 gene, designated P1b, as illustrated in Figure 1.

20

In the present context the term "promoter" is meant to include core promoter sequences proximal to the start of transcription and upstream promoter elements which bind constitutively active transcription factors, as well as distal promoter elements which bind specific transcription factors.

25

Accordingly, the present invention provides a nucleic acid molecule constituting a human GABA<sub>B</sub> receptor 1 promoter P1a, or a functionally equivalent modified form thereof, or active fragments thereof. The present invention also provides a nucleic acid molecule constituting a human GABA<sub>B</sub> receptor 1 promoter P1b, or a functionally equivalent

30

modified form thereof, or active fragments thereof. By a functionally equivalent modified form is understood nucleic acids modified from the original sequence that can bind transcription factors. By active fragments of the promoters is understood nucleic acid fragments that can bind transcription factors.

5

In preferred forms of the invention the said nucleic acid molecule is selected from:

- (a) a nucleic acid molecule comprising a nucleotide sequence set forth as SEQ ID NO: 1;
- (b) a nucleic acid molecule comprising a nucleotide sequence capable of hybridizing, under stringent conditions, to a nucleotide sequence complementary to the DNA molecule as

10

defined in (a).

In other preferred forms of the invention the said nucleic acid molecule is selected from:

- (a) a nucleic acid molecule comprising a nucleotide sequence set forth as SEQ ID NO: 2;
- (b) a nucleic acid molecule comprising a nucleotide sequence capable of hybridizing, under

15

stringent conditions, to a nucleotide sequence complementary to the DNA molecule as defined in (a).

In another preferred form of the invention the said nucleic acid molecule may be a nucleic

acid molecule constituting a human GABA<sub>B</sub> receptor 1 promoter P1a, or a functionally

equivalent modified form thereof, or active fragments thereof, in combination with a

nucleic acid molecule constituting a human GABA<sub>B</sub> receptor 1 promoter P1b, or a

functionally equivalent modified form thereof, or active fragments thereof.

20

In another preferred form of the invention the said nucleic acid molecule may be a nucleic acid molecule selected from:

- (a) a nucleic acid molecule comprising a nucleotide sequence set forth as SEQ ID NO: 1;
- (b) a nucleic acid molecule comprising a nucleotide sequence capable of hybridizing, under stringent conditions, to a nucleotide sequence complementary to the DNA molecule as

30

defined in (a);

in combination with a nucleic acid molecule is selected from:



- (a) a nucleic acid molecule comprising a nucleotide sequence set forth as SEQ ID NO: 2;  
(b) a nucleic acid molecule comprising a nucleotide sequence capable of hybridizing, under stringent conditions, to a nucleotide sequence complementary to the DNA molecule as defined in (a).

5

It should thus be understood that the nucleic acid molecules according to the invention is not to be limited strictly to molecules comprising the sequences set forth as SEQ ID : 1 and 2. Rather the invention encompasses nucleic acid molecules carrying modifications like substitutions, small deletions, insertions or inversions, which nevertheless have  
10 substantially the biochemical activity of the GABA<sub>B</sub> receptor promoters 1a and/or 1b according to the invention. Included in the invention are consequently nucleic acid molecules, the nucleotide sequence of which is at least 95% homologous, preferably at least 96%, 97%, 98% or 99% homologous, with the nucleotide sequence shown as SEQ ID NO: 1 or 2 in the Sequence Listing.

15

The term "stringent hybridization conditions" is known in the art from standard protocols (e.g. Current Protocols in Molecular Biology, editors F. Ausubel et al., John Wiley and Sons, Inc. 1994) and could be understood as as stringent or more stringent than those defined by e.g. hybridization to filter-bound DNA in 0.5 M NaHPO<sub>4</sub>, 7% sodium dodecyl  
20 sulfate (SDS), 1 mM EDTA at +65°C, and washing in 0.1xSSC / 0.1% SDS at +68°C.

It will be appreciated that the nucleic acid sequences shown in the Sequence Listing is only an example within a large but definite group of nucleic acid sequences, which will have the GABA<sub>B</sub> receptor promoter activity.

25

In yet another aspect, the invention provides a vector transformed with a nucleic acid molecule of the present invention. The said vector can e.g. be a replicable expression vector, which carries a nucleic acid molecule according to the invention. In the present context the term "replicable" means that the vector is able to replicate in a given type of  
30 host cell into which is has been introduced. Examples of vectors are viruses such as

bacteriophages, cosmids, plasmids and other recombination vectors. Nucleic acid molecules are inserted into vector genomes by methods well known in the art.

Another embodiment of the present invention is an expression system comprising nucleic acid molecules encoding GABA<sub>B</sub> receptor promoters P1a and/or P1b, or functionally equivalent modified forms, or active fragments thereof.

In preferred forms of this embodiment of the invention the said nucleic acid molecule is selected from: (a) a nucleic acid molecule comprising a nucleotide sequence set forth as SEQ ID NO: 1 and/or SEQ ID NO: 2 ; (b) a nucleic acid molecule comprising a nucleotide sequence capable of hybridizing, under stringent conditions, to a nucleotide sequence complementary to the polypeptide coding region of a DNA molecule as defined in (a).

In another preferred form of this embodiment of the invention the said nucleic acid molecule may be a nucleic acid molecule constituting a human GABA<sub>B</sub> receptor 1 promoter P1a, or a functionally equivalent modified form thereof, or active fragments thereof, in combination with a nucleic acid molecule constituting a human GABA<sub>B</sub> receptor 1 promoter P1b, or a functionally equivalent modified form thereof, or active fragments thereof.

In another preferred form of this embodiment of the invention the said nucleic acid molecule may be a nucleic acid molecule selected from:

(a) a nucleic acid molecule comprising a nucleotide sequence set forth as SEQ ID NO: 1;  
(b) a nucleic acid molecule comprising a nucleotide sequence capable of hybridizing, under stringent conditions, to a nucleotide sequence complementary to the DNA molecule as defined in (a);

in combination with a nucleic acid molecule is selected from:

(a) a nucleic acid molecule comprising a nucleotide sequence set forth as SEQ ID NO: 2;  
(b) a nucleic acid molecule comprising a nucleotide sequence capable of hybridizing, under stringent conditions, to a nucleotide sequence complementary to the DNA molecule as defined in (a).

The expression system may, in addition, comprise a reporter gene, the promoter and the reporter gene being positioned so that the expression of the reporter gene is regulated by the GABA<sub>B</sub> receptor 1 promoters P1a and/or P1b. Suitable expression systems according to the invention are e.g. bacterial or yeast plasmids, wide host range plasmids and vectors derived from combinations of plasmid and phage or virus DNA. Furthermore, an origin of replication and/or a dominant selection marker can be present in the vector according to the invention. Suitable reporter genes that can be used for the construction of expression systems according to the invention are e.g. the firefly luciferase gene, the bacterial chloramphenicol acetyl transferase (CAT) gene, the  $\beta$ -galactosidase ( $\beta$ -GAL) gene, and the green fluorescent protein (GFP).

A further aspect of this embodiment of the invention is a host cell transfected with an expression system comprising nucleic acid molecules constituting GABA<sub>B</sub> receptor promoters P1a and/or P1b, or functionally equivalent modified forms thereof, or active fragments thereof.

Suitable host cells are cells known to express GABA<sub>B</sub> receptors or cells known to express transcription factors, which can influence the transcription of GABA<sub>B</sub> receptors. Host cells transfected with DNA encoding specific transcription factors can preferably be used to study the interaction with defined transcription factors and the GABA<sub>B</sub> receptor promoter.

Another embodiment of the invention is a method for the assay of GABA<sub>B</sub> receptor promoter activity said method comprising the use of a host cell transfected with an expression system comprising nucleic acid molecules constituting GABA<sub>B</sub> receptor promoters P1a and/or P1b, or functionally equivalent modified forms thereof, or active fragments thereof.

A further embodiment of the present invention is a method for the screening of compounds which are modulators of GABA<sub>B</sub> receptor 1 transcription, said method comprising the use of nucleic acid molecules constituting GABA<sub>B</sub> receptor P1a and/or P1b promoters.

5 Accordingly, the present invention provides a method for screening compounds which are modulators of GABA<sub>B</sub> receptor 1 transcription, comprising the steps of: (a) transfecting a cell host with a suitable expression system comprising a nucleic acid molecule constituting human GABA<sub>B</sub> receptor 1 promoter P1A, and/or a human GABA<sub>B</sub> receptor 1 promoter P1B or functionally equivalent modified forms, or active fragments thereof coupled to a  
10 reporter gene; (b) contacting a test compound with the cell; and (c) determining whether the test compound modulates the level of expression of the reporter gene.

In one aspect of this embodiment of the invention it is provided a method of screening of compounds which are modulators of GABA<sub>B</sub> receptor 1 transcription, wherein the cell host  
15 endogenously expresses GABA<sub>B</sub> receptor 1.

In another aspect of this embodiment of the invention it is provided a method of screening of compounds which are modulators of GABA<sub>B</sub> receptor 1 transcription, wherein the said cell host is further transfected with a suitable expression system comprising a nucleic acid  
20 molecule encoding one or more specific transcription factors. Preferably, the said transcription factors are selected from the group: CREB-1, CREB-2, CREM-1, ATF-1, ATF-2, ATF-3, ATF-4, Sp1, Sp2, Sp3, Sp4, AP-1, and AP-2.

A further embodiment of the invention is a transgenic non-human animal whose genome  
25 comprises an expression system comprising nucleic acid molecules constituting GABA<sub>B</sub> receptor promoters P1a and/or P1b, or functionally equivalent modified forms thereof, or active fragments thereof, coupled to a reporter gene.

Such transgenic non-human mammals can be generated by insertion of DNA comprising  
30 GABA<sub>B</sub> receptor promoters by microinjection, retroviral infection or other means well known to those skilled in the art, into appropriate fertilized embryos to produce a

transgenic animal (Hogan B. et al Manipulating the Mouse Embryo. A Laboratory Manual. Cold Spring Harbor Laboratory (1986)).

Accordingly, the present invention provides a method for the screening of compounds which are modulators of GABA<sub>B</sub> receptor 1 transcription, comprising the use of a transgenic non-human animal whose genome comprises an expression system comprising nucleic acid molecules constituting GABA<sub>B</sub> receptor promoters P1a and/or P1b, or functionally equivalent modified forms thereof, or active fragments thereof, coupled to a reporter gene, or tissues or cells isolated from such transgenic animals.

## EXAMPLES

The following examples are preferred non-limiting examples embodying preferred aspects of the invention.

### Example 1. Isolation and identification of human GABA<sub>B</sub> R1 promoters P1a and P1b

Genomic DNA containing the human GABA<sub>B</sub> receptor gene was isolated from human genomic libraries and genomic DNA. Human genomic libraries were obtained from Clontech (Palo Alto, CA, USA). The libraries were constructed from female leukocyte DNA (catalogue # HL1111J), cloned into  $\lambda$ EMBL-3 vector. The average size of inserts are 16 kb and the number of independent clones are  $1.7 \times 10^6$ . Human genomic DNA was obtained from Clontech (catalogue # 6550-1). In order to isolate recombinant phases containing exon and intron sequences of the human GABA<sub>B</sub> receptor gene, 48 individual bacterial plates with a diameter of 150 mm and approximately  $4 \times 10^4$  individual plaques per plate, were screened. The methods and solutions used were as described in the Library Protocol Handbook: General Procedures for the Hybridization of Lambda Phage Libraries w/DNA Probes (Clontech) with some modifications as will be apparent from the following.

The experiment was carried out essentially as follows. The numbers are given per plate basis. A sample of the phage library diluted in 0.1 ml sterile lambda diluent was prepared in order to obtain an estimated titer of 40,000 pfu (plaque forming units). A 0.6 ml LB-medium culture of the *E. coli* host strain K802 (obtained from Clontech) was infected with 40000 pfu recombinant phages for 15 minutes at 37°C. The culture was then mixed with 7 ml top agarose (6.5 g of agarose added per liter LB) and poured onto LB plates. The plates were incubated at 37°C for approximately 7 hours. The plates were then chilled at +4°C.

Plaque hybridization experiments were as follows. Membrane filters, Colony/Plaque Screen (DuPont, Wilmington, DE, USA), were placed onto the top of the plates for 3 minutes. For denaturation of DNA the filters were removed and floated in 0.5 M NaOH on a plastic wrap for 2 minutes, with the plaque side up. This step was repeated once to ensure efficient denaturation. Following neutralization the membrane filters were placed in 1M Tris-HCl pH 7.5, two times 2 minutes and allowed to dry.

To obtain probes for DNA hybridization screening of the membrane filters, a GABA<sub>B</sub> receptor cDNA clone was digested with SacII and a 479 bp fragment, separated by agarose electrophoresis, excised and transferred to a polypropylene microcentrifuge tube.

Additional probes were obtained by PCR amplification of various regions of the GABA<sub>B</sub> receptor cDNA. The isolated cDNA fragment was <sup>32</sup>P-labeled using Megaprime DNA labeling system (Amersham Pharmacia Biotech, Uppsala, Sweden) by the following procedure. Water was added at a ratio of 3 ml per gram of gel, and placed in a boiling water bath for 7 minutes to melt the gel and denature the DNA. A volume of DNA/agarose solution containing 25 ng of DNA was added to the labeling reaction, according to the supplier's instructions. Labeled nucleotides were removed from DNA labeling reactions using MicroSpin<sup>TM</sup> G-50 Columns (Amersham Pharmacia Biotech, Uppsala, Sweden ).

The DNA hybridization reaction was performed under stringent conditions according to the method described below. The filter membranes were prehybridized at 65°C for at least 1 hour in a solution composed of 1% SDS, 1M NaCl, and 10% dextran sulfate using a

hybridization oven (Hybaid Ltd, Ashford, UK). Following prehybridization a solution containing denatured herring sperm DNA of a final concentration of 100  $\mu\text{g/ml}$  and the  $^{32}\text{P}$ -labeled DNA probe at a concentration  $<10\text{ ng/ml}$  (for optimal signal to background ratio) was added to the prehybridization solution and the membrane filters were incubated at 65°C for 10-20 hours. Following the removal of the hybridization solution the membrane filters were first washed in a 2xSSC (0.3M NaCl, 0.03M Na-citrate), 1% SDS solution two times for 5 minutes at room temperature. In the next step, the membrane filters were incubated at 60°C two times for 30 minutes each in the same solution. In a third step, the filters were washed two times at room temperature in 0.1xSSC. Finally, the membrane filters were placed on a sheet of filter paper with the DNA face up, and allowed to dry. The dried membrane filters were then exposed to X-ray films and autoradiographed.

Of the approximately  $2 \times 10^6$  individual plaques analyzed, four hybridizing plaques were detected and isolated. These four isolates were designated #GR1, #GR12, #GR13 and #GR41, respectively. After several rescreening experiments, the recombinant phage DNA was purified using Qiagen Lambda Midi Kit (Qiagen GmbH, Germany). The purified DNA was digested with SalI and the fragments representing the inserts were isolated by agarose electrophoresis.

The 16kb insert of isolate #GR13 was cloned into SalI digested linearized pUC19, resulting in the plasmid pAM364. The insert was analyzed by PCR, restriction mapping and hybridization to  $^{32}\text{P}$ -labeled DNA fragments representing various regions of the GABA<sub>B</sub> receptor cDNA.

The cloned fragment in the plasmid pAM364 was characterized by restriction enzyme mapping, using EcoRI, HindIII, PstI, and BamHI. The approximate positions of the exons and the approximate size of the introns were analyzed and determined by PCR-based exon-exon linking and agarose gel electrophoresis.

In order to facilitate nucleotide sequence analysis, 7 restriction sub-fragments derived from pAM364 were isolated and cloned individually into pUC19. The following strategy was

employed: by combining PCR primers located within the pUC19 sequence either upstream or downstream of the cloning site, with a PCR primer with defined orientation and specific for the GABA<sub>B</sub> receptor derived subcloned fragment allowed the sequence determination.

5 The inserts were subjected to nucleotide sequence analysis. The nucleotide sequences for all subclones were determined using a Thermo Sequenase dye terminator cycle sequencing pre-mix kit (Amersham Pharmacia Biotech, Uppsala, Sweden). As primers for sequencing reactions specific oligonucleotides complementary to pUC19 or primers complementary to the human GABA<sub>B</sub> receptor cDNA were used.

10

The sequence of the human GABA<sub>B</sub> receptor gene fragment cloned in the plasmid pAM364 has previously been revealed (see PCT/SE98/01947). This genomic fragment was shown to contain the complete exons 1-11 and the complete introns 1-10 of the human GABA<sub>B</sub> receptor gene as well as > 3kb sequence upstream of exon 1. The elucidation of  
15 the gene organization revealed that the human GABA<sub>B</sub>R1a and GABA<sub>B</sub>R1b are splice variants encoded by a single gene.

In order to localize the putative human GABA<sub>B</sub> receptor promoter, we investigated the genomic sequence for the presence of consensus sequences of known regulatory promoter  
20 elements. To our surprise, we found that promoter elements, clustered in two regions: one region upstream of exon 1, and the other region in intron 5, just upstream of exon 6. We concluded that the human GABA<sub>B</sub> receptor may be regulated by two independent promoters, and not by one single promoter as expected. The first putative promoter, denoted P1a (SEQ ID NO: 1) and described in detail below, may regulate transcription of  
25 GABA<sub>B</sub>R1a-type splice variants and the second putative promoter, denoted P1b (SEQ ID NO: 2) and described in detail below, may regulate transcription of GABA<sub>B</sub>R1b-type splice variants.

As indicated in the schematic representation of P1a and P1b (Figure 2), both putative  
30 promoters lack a TATA box. However P1b has an initiator (Inr) element in position 4375-4381 which is located 24-30 bp upstream of the position corresponding to the 5' end of the



longest known cDNA isolated with "rapid amplification of cDNA ends" (RACE) PCR amplification. The Inr element may therefore direct the start of transcription from P1b. P1a contains neither a TATA or an Inr element and the transcription from R1a may therefore initiate from different start sites which is often the case in promoters lacking TATA boxes or Inr elements. Both P1a and P1b contain multiple GC rich regions at pos. 3009-3016, 3037-3044 and 3116-3123 in R1a and pos. 4080-4087, 4196-4204, 4241-4249 and 4272-4279 in R1b, which are potential binding site for the SP1 family of transcription factors. SP1 binding sites are often found in TATA lacking promoters where they often substantially contribute to transcription. In addition, to the indicated GC sequences in Figure 2 there are also other GC motifs that may function as SP1 binding sites. P1a further contains an activator protein-1 (AP-1) site at position 1497-1503. AP-1 sites are recognized by AP-1 transcription factors which consists of homodimers of members of the Jun family or Fos/Jun heterodimeric complexes. AP-1 complexes also interact, by protein-protein interactions, with members of the steroid receptor family and are therefore also targets for steroid receptor signaling. In addition to the GC motifs P1b also contain an activator protein-2 (AP-2) site at position 3844-3851 and a cAMP responsive element (CRE) at position 4308-4315. Especially the finding of a consensus CRE (TGACGTCA) is interesting as this promoter element is found in many genes regulated by cAMP which are bound and regulated by members of the ATF/CREB gene family. This sequence may therefore be an important target for cAMP mediated signaling via G-protein coupled receptors, including GABA<sub>B</sub> receptors.

We conclude that transcription of the human GABA<sub>B</sub> receptor gene may be regulated by two putative promoters, P1a and P1b, that may independently regulate expression of human GABA<sub>B</sub> receptor 1a and 1b splice isoforms, respectively.

### Example 2. Determination of GABA<sub>B</sub> R1 promoter P1a and P1b activity

- 5 To experimentally determine if P1a and P1b indeed act as promoters, we fused these regions to a cDNA encoding firefly luciferase to be used as a reporter of promoter activity in transfected cells.

Reporter constructs containing R1a and R1b promoter fragments were generated by PCR  
 10 using plasmid pAM 364, containing genomic sequence covering the promoter regions, as template. PCR reaction was performed by standard procedure (Perkin Elmer). Briefly, an initial denaturation at 95°C for 4 min was followed by 35 cycles of denaturation at 95°C for 1 min, annealing at 60°C for 1 min, elongation at 72°C for 1 min and finally a 7 min elongation at 72°C. In the sequence for primers used to generate promoter fragments (for  
 15 details see Table 1. below), a Nhe I and Hind III endonuclease restriction enzyme site was introduced, in 5' and 3' primers respectively, to enable sub-cloning into Nhe I/Hind III digested pGL3-Basic luciferase reporter vector (Promega). Hence, complete promoter-reporter constructs (pAM440, pAM438 and pAM436) contain R1a and R1b promoter fragments (indicated size see table) fused to the luciferase reporter gene. Plasmid DNA  
 20 were purified using Qiagen tip-100 columns according to suppliers instruction. Correct fragment insertion was verified by DNA sequencing.

25 Table 1. Nucleotide sequence of primers used to generate promoter fragments

Primer No.	Restriction site	Promoter sequence	Position	Sequence 5'-3'
1582	HindIII (AAG CTT)	SEQ ID NO: 1	3440-3424	AAG CTT CTC GGC GCG CGG GCC CG
1583	NheI (GCT AGC)	SEQ ID NO: 1	2341-2362	GCT AGC CAA GAG CTT CTG GAG CCG
1584	NheI (GCT AGC)	SEQ ID NO: 1	720-741	GCT AGC TGT TAC ATG CAG AGC AAT C
1585	HindIII (AAG CTT)	SEQ ID NO: 2	4439-4421	AAG CTT CCT ACG GCC CCC GCG
1586	NheI (GCT AGC)	SEQ ID NO: 2	3321-3340	GCT AGC GCG CAC TGC AAT GCC CTC

To determine putative promoter activity, the reporter gene constructs were introduced into mammalian cells by transfection. In this study the cell line ND7/23 (ECACC Ref No: 92090903) was used. ND7/23 is a hybrid cell line originating from a mouse neuroblastoma (N18tg2) fused by PEG to a rat dorsal root ganglion neuron cell line. This cell line was chosen since it express functional GABA<sub>B</sub> receptors as evidenced by radioligand binding studies. Cells were cultured in a 1:1 mixture of Dulbecco's modified medium (DMEM) and Ham's F12 medium supplemented with 10% (v/v) fetal bovine serum (FBS). Cells were grown at 37°C in an atmosphere of 5% CO<sub>2</sub>. ND7/23 cells ( $4 \times 10^5$ ) were transfected using the DMRIE-C reagent according to manufacturer's protocol (Gibco). Briefly, cells were seeded in 6 well tissue culture plates (Nunc) the day before transfection. Next day, 2 µg of promoter-reporter construct and 1 µg of transfection control construct (pSV-β-Galactosidase, Promega) was mixed with 0.5 ml Optimem media (Gibco). DNA containing media was then mixed with an equal volume (0.5ml) of Optimem containing 4 µl of DMRIE-C reagent and the combined mixture was then incubated for 45 min. After incubation, the transfection mixture was added to the cells, which were washed with Optimem media just prior to addition of transfection mixture. Following 5h incubation at 37°C, an equal volume of 1:1 mixture of Dulbecco's modified medium (DMEM) and Ham's F12 medium supplemented with 20% (v/v) fetal bovine serum (FBS) was added to the cells. Cells were incubated for 24h at 37°C with or without cAMP enhancing supplement as indicated in Figure 3. Before cell harvest, cells were washed in PBS (7.6 mM Na<sub>2</sub>HPO<sub>4</sub>/NaH<sub>2</sub>PO<sub>4</sub> pH 7.4 and 120 mM NaCl), then cell extracts were prepared by addition of 250 µl reporter lysis buffer (Promega) to cells, followed by transfer of cell suspension to 1.5 ml tubes. Cells were further lysed by one round of freeze-thawing and 15s of vortex. Cell debris were removed by 2 minutes of centrifugation at 12 000 g. Luciferase activity in cell extracts was measured in a Luciferase Assay System (Promega), where 40 µl of cell extracts was added to a 96-well plate (Maxisorp. Nunc) and mixed with 50 µl of luciferase substrate. Luciferase activity was then measured in a LUMIstar (BMG Lab technologies). As internal control for transfection efficiency, β-Galactosidase (β-Gal.) activity was measured in 96-well plate (Maxisorp. Nunc) using a β-Galactosidase Enzyme

Assay (Promega) according to suppliers protocol. As seen in Figure 3, transient transfection of ND7/23 cells shows that both P1a and P1b has promoter activity as pAM438, pAM436 and pAM440 (Figure 3) result in reporter expression, while the pAM442 (vector control) has very low activity. In addition, this experiment demonstrates that especially reporter expression originating from pAM440 (R1b) can be induced by the cAMP activating agent forskolin. Moreover, forskolin induced expression may also be further enhanced in the presence of the phosphodiesterase inhibitor 1-methyl-3-isobutylxanthine (IBMX) although this experiment does not show a significant difference.

In conclusion, this experiment demonstrate that P1a and P1b both have promoter activity and that the degree of activity can be modulated using the cAMP activating agent forskoline.

### Example 3. Screening for substances modulating P1a and P1b activity

Modulating GABA<sub>B</sub>R1 expression in a controlled way is a means to regulate signaling through GABA<sub>B</sub> receptors which could be of significant therapeutic value for a variety of conditions. Particularly, the ability to specifically regulate expression of either 1a- or 1b-type GABA<sub>B</sub> receptor splice isoforms could be of medical value if these isoforms could be attributed to specific conditions.

The experiment presented in Example 2 demonstrates that the use of P1a and P1b promoter/reporter constructions can be used to monitor GABA<sub>B</sub> R1 expression in screens for therapeutic agents that can modify the expression of GABA<sub>B</sub> receptor 1 isoforms. A screen for P1a and P1b modulating substances could be performed in ND7/23 cells as described in Example 2. A screen for P1a and P1b modulating substances could in addition be performed in any cell type with endogenous expression of GABA<sub>B</sub> receptor 1 and 2 isoforms, in cells expressing recombinant GABA<sub>B</sub> receptor 1 and 2 isoforms and in intact cells and in extract or fractions of cells expressing endogenous and recombinant proteins

modulating GABA<sub>B</sub> receptor function. Such screens could furthermore be done in tissues and in living organisms.

Example 4. Functional analysis of GABA<sub>B</sub>-R1 promoter fragments and modified forms

5

In order to identify functionally active promoter fragments of P1a and P1b, a deletion analysis of DNA fragments containing promoter fragments can be performed in two steps.

10

It is anticipated that P1a and P1b comprise active fragments that can mediate increased expression by binding of transcription factors that are activators as well as active fragments which can mediate decreased expression by binding of transcription factors that are repressors.

15

In the first step, promoter fragments mediating expression of a reporter gene when used in reporter constructs can be stepwise deleted or truncated to identify important regions. Briefly, truncated or deleted promoter fragments are created by PCR using specific primers and the already identified promoter sequences as template. Reporter constructs (as exemplified in this application) comprising the deleted or truncated promoter fragments are then created. These reporter constructs can then be used in transfection experiments, as described above, to identify important regions of the promoters manifested in altered expression from constructs lacking active fragments compared to none-deleted constructs.

20

25

In the second step, the exact location and sequence of transcription factor binding sites within active fragments can be determined by PCR technique using specific primers harbouring desired mutations. Such promoter fragments, with specifically mutated promoter regions, can be used in transfection experiments, similar to those described above, to determine the exact sequence of functionally important nuclear factor binding sites within active promoter fragments, manifested in altered expression from constructs with mutated DNA sequence compared to none-mutated control constructs with equal size.

30

The above mentioned strategy can also be used to identify the specific active promoter fragments which are important for the effect on promoter activity of active substances identified when screening for therapeutic agents regulating GABA<sub>B</sub>-R1 expression.

5 Example 5. Activity of GABA<sub>B</sub> R1 promoter P1a and P1b fragments.

Reporter constructs containing P1a and P1b promoter fragments were generated by PCR as described in Example 2 and fused to the firefly luciferase reporter gene. The generated constructs are visualised in Figure 4.

10

Putative transcription initiation sites were identified at position 3207 in SEQ ID NO:1 for P1a and at position 4405 in SEQ ID NO:2 for P1b. The positions in the promoter region shown in Figure 4 were calculated setting the transcription initiation sites as position +1.

15

The generated promoter reporter constructs (see Figure 4) were used to transfect ND7/23 cells. As shown in Figure 4, deletion of P1a promoter region in between position -2549 bp and -361 caused an increase in expression, indicating putative repressor regions between position -2549 and -361. Moreover, when 175 bp of the 5' untranslated region were removed (compare the third and fourth P1a constructs from the top) there was no detected difference in promoter activity and constructs with the shorter P1a 5'-untranslated region were therefore used for mutational analysis throughout the rest of the study. Additional deletions of the P1a promoter from position -361 to -46 caused a stepwise decrease of the expression that seem to correlate with removal of promoter regions containing GC elements (I-III). This indicate that 361 bp of the P1a promoter can confer optimal expression and that promoter elements essential for R1a-type expression, including GC elements I-III are located between position -361 and -46. Similar to the P1a promoter, deletion of P1b promoter region from position -3238 bp to -390 caused an increase in expression, indicating putative repressor regions between -1084 and -390. Also, additional deletions of the P1b promoter from position -390 to -88 caused a stepwise decrease of the expression that correlate with removal of promoter region GC elements (IV-VII) as well as the consensus CRE. Although there was still some promoter activity left when the P1b

25

30

promoter region was deleted down to position -88. the major promoter elements essential for R1b-type expression seem to be located between position -390 and -88. Comparison of P1a and P1b expression also indicates that, P1b mediated expression was higher (approximately 3-4 fold) than for P1a.

#### Example 6. Mutational analysis of P1a and P1b promoter element function

As shown in Figure. 4, reporter constructs -361 in P1a (short 5'UTR) and -390 in P1b conferred optimal expression of the respective promoters. In order to determine the importance of the promoter elements that was found within these regions, P1a (-361) and P1b (-390) constructs were used as templates to obtain reporter constructs with promoter regions mutated at specific sites. For the mutated promoter constructs, a 3 bp substitution was introduced by "quick change" site directed mutagenesis.

*Site-directed mutagenesis:* Mutant constructs were prepared with a QuickChange site-directed mutagenesis kit (Stratagene, La Jolla, CA) according to the manufacturer's instructions. The mutagenic oligonucleotide primers are listed in Table 2. All constructs were verified by DNA sequencing.

Table 2. Oligonucleotide primers used in the mutagenesis experiments

Primer	Primer Sequences
1949 P R1b Cre Fwd	CGCCGCCCCGTTTGGTCAGAGCCCCCT
1950 P R1b Cre Rev	AGGGGGCTCTGACCAAACGGGCGGCG
1951 P R1a GCI Fwd	CTCTCTTCCCCCTAACTGCCTTCCC
1952 P R1a GCI Rev	GGGAAGGCAGTTAGGGGGGAAGAGAG

1953	P R1a GCII Fwd	GGCGGTCCAG <b>TT</b> AGGGGCTGGGATCC
1954	P R1a GCII Rev	GGATCCCAGCCCC <b>TAA</b> CTGGACCGCC
2051	P R1a GCIII Fwd	CCTCTCCACCGCCC <b>TA</b> ACCACCGCGCTGTG
2052	P R1a GCIII Rev	CACAGCGCGGTGG <b>TT</b> AGGGCGGTGGAGAGG
2053	P R1b GCIVs Fwd	CCCCAGCTCCCGCC <b>TA</b> ACCCCCACCCC
2054	P R1b GCIVs Rev	GGGGTGGGGG <b>TT</b> AGGGCGGGAGCTGGGG
2055	P R1b GCV Fwd	CGCTTCCCTCCCC <b>TA</b> ACCCTTCCTGCC
2056	P R1b GCV Rev	GGCAGGAAGGG <b>TT</b> AGGGGAGGGAAGCG
2057	P R1b GCVI Fwd	CCCTCCCCTCCCC <b>TA</b> ACCTCCGACTGT
2058	P R1b GCVI Rev	ACAGTCGGAGG <b>TT</b> AGGGGAGGGGAGGG
2059	P R1b GCVII Fwd	CTCCGCCCCACCC <b>TA</b> ACTCCTGGCAC
2060	P R1b GCVII Rev	GTGCCAGGAG <b>TT</b> AGGGGTGGGCGGAG
2146	P R1b GCIVd Fwd	CCCCAGCTCC <b>TA</b> ACT <b>TA</b> ACCCCCACCCC
2147	P R1b GCIVd Rev	GGGGTGGGGG <b>TT</b> AG <b>TT</b> AGGGAGCTGGGG

Bases that are labelled bold correspond to designed mutations

- 5 Obtained promoter constructs were then used to transfect ND7/23 cells. As shown in Figure 5, single point mutations of GC elements I, II and III reduced P1a expression to approximately 65-75% compared to wild-type, while double-mutations (I/II, I/III and II/III, respectively) resulted in a further decrease to approximately 55-60% of wild-type expression levels. When all three GC elements (I-III) were mutated, the reporter expression
- 10 was reduced to approximately one third (33%) of wild-type expression. Together, these results suggest that the three GC-elements found in P1a, all contribute to P1a mediated expression in a substantial and additive manner. However, the fact that one third of the P1a promoter activity still remains suggests that there are additional promoter elements within P1a contributing to P1a mediated expression.



In contrast to P1a, single mutations of the four P1b GC elements (IV, V, VI and VII) only caused small reductions of expression to approximately 75-90% compared to wild-type. The relatively modest contribution by the four P1b GC elements was also demonstrated by a promoter construct where all four GC elements (IV-VII) had been mutated. This construct retained 63% of P1b expression compared to the wild-type construct. However, when the P1b CRE consensus site was mutated (CRE), a dramatic reduction of P1b mediated expression (approximately 50%) was obtained. Moreover, when the CRE mutation was combined with mutations of each GC element respectively, a further reduction was observed. Most notably, the promoter construct containing a double mutation of the CRE and GC V (CRE/V) promoter elements resulted in a substantial reduction of P1b expression to approximately 26%, similar to the construct where all five P1b promoter elements were mutated (CRE/IV-VII) where 24% of the expression still remained compared to wild-type. Together these data demonstrates the absolute importance of the consensus CRE site for P1b expression, alone or in combination with the GC elements (IV, V, VI and VII), of which GC element V seems to contribute most. The fact that one fourth of P1b promoter activity still remains suggests that, as for P1a, there are additional promoter elements within P1b that may contribute to P1b mediated expression.

#### Example 7. Identification of factors interacting with the P1b CRE site

##### *Electrophoretic mobility shift assays (EMSA)*

Electrophoretic mobility shift assays (EMSA) can be used to identify nuclear factors that interact with P1a and P1b promoter elements. In an attempt to identify factors interacting with the P1b CRE site, we performed gelshift analysis with super-shift antibodies that recognise members of the CREB/ATF family of transcription factors. The DNA-binding reactions (12 µl) were done as follows; 2-3 fmol <sup>32</sup>P-labeled double-stranded oligonucleotide corresponding to the P1b CRE site was mixed with 5 µg crude nuclear extracts from ND7/23 cells and 1 µg poly (dI-dC), 25mM Hepes (pH 7,9), 150 mM KCl, 5 mM dithiothreitol and 10% glycerol (Schneider et al 1986, Nucleic Acids Research. 14:1303-17). In the supershift lane (Figure 6) the ATF-1 p35/CREB-1 p43/CREM-1

reactive antibody (sc-270 from Santa Cruz Biotechnology, Santa Cruz, CA), was pre-incubated at room temperature for 20 min before addition of  $^{32}\text{P}$ -labeled probe. After incubation at room temperature for 15 min, protein-DNA complexes were resolved on precasted DNA-retard gels (Novex<sup>TM</sup>) containing 6% polyacrylamide prepared with 0.5x TBE as gel buffer. . Following electrophoresis, gels were dried and visualised by autoradiography.

As shown in Figure 6, addition of a monoclonal CREB/ATF supershift antibody (reactive with members of the ATF/CREB family such as ATF-1 p35, CREB-1 p43 and CREM-1 of mouse, rat and human origin) into the EMSA reaction mixture results in a distinct shift of the nuclear factor(s) that interacts with the P1b CRE site, while no super-shift was observed when the same antibody was added to other EMSA reactions containing other promoter elements (data not shown). This data suggests that the complex formed with the P1b CRE site contains a member of the CREB/ATF family.

Similar further studies can be performed in order to determine which factor(s) that interact with the various promoter elements in P1a and P1b .

#### Example 8. Use of recombinant transcription factors in the study of P1a and P1b promoter activities.

Cells with stably integrated or with transiently transfected P1a/P1b reporter constructs can be transfected with cDNA encoding specific transcription factors to make reporter cells suitable for investigations of P1a and P1b activities mediated by said transcription factors. Reporter cells can alternatively be generated by delivery of transcription factors into similar cells by various means such as e.g. microinjection and lipofection. Reporter cells can be utilised for screening of compounds, which are modulators of GABA<sub>B</sub> receptor 1 transcription.

## BRIEF DESCRIPTION OF DRAWINGS

5

Figure 1. The human GABA<sub>B</sub> receptor gene

The figure shows the organization of the human GABA<sub>B</sub> receptor gene. Exons, represented by vertical squares/bars, are numbered (1-23). Translational start and stop sites are indicated by arrows. Location of human GABA<sub>B</sub> receptor 1 promoters P1a (SEQ ID NO: 1) and P1b (SEQ ID NO: 2) are indicated. The extent of human GABA<sub>B</sub> receptor genomic sequence cloned in plasmid pAM 364 is indicated by a horizontal bar.

15 Figure 2. Schematic representation of the P1a and P1b promoters

DNA fragments used to generate reporter constructs, corresponding to the positions in the P1a and P1b promoter sequence, are shown below each promoter. Putative promoter elements in each promoter are indicated. Arrows indicate putative positions for start of transcription.

20

Figure 3. Determination of GABA<sub>B</sub> receptor 1 promoter P1a and P1b activity

25 ND7/23 cells ( $4 \times 10^5$ ) were transfected with promoter-luciferase constructs as described above. After transfection, cells were cultured in media without supplement (basal) or in the presence of Forskolin (10 $\mu$ M) or Forskolin (10 $\mu$ M) + 1-methyl-3-isobutylxanthine (0.125mM) for 24h. After incubation, cells were harvested and luciferase activity measured. Luciferase activity, minus background, is shown as arbitrary light units measured in 40  $\mu$ l of cell extracts. Relative values represent the mean $\pm$ SEM of two individual experiments.

30

Figure 4: Deletion analysis of the GBR1 promoters in ND7/23 cells

5 ND7/23 cells ( $4 \times 10^5$ ) were transfected with P1a and P1b promoter-luciferase constructs as outlined above. After transfection, cells were cultured for 24h, harvested and luciferase activity was measured. Luciferase activity, minus background, is shown as arbitrary light units measured in 10  $\mu$ l of cell extracts. Relative values represent the mean  $\pm$  SEM of duplicate samples from at least three individual experiments.

Figure 5. Effect of P1a and P1b promoter element mutations on promoter activities.

15 ND7/23 cells ( $4 \times 10^5$ ) were transfected with wild-type and mutated P1a and P1b promoter-luciferase constructs as described above. The point mutations in the promoter constructs are outlined to the left. After transfection, the cells were cultured for 24h. After incubation, cells were harvested and luciferase activity measured. Luciferase activity, minus background, is shown as arbitrary light units measured in 10  $\mu$ l of cell extracts. Relative values represent the mean  $\pm$  SEM of duplicate samples from at least three individual experiments. Relative expression level of mutated constructs are indicated to the left with the P1a and P1b "wild-type" expression level set as 100%.

Figure 6. Identification of nuclear factors binding to the P1b consensus CRE site using  
25 CREB/ATF super-shift antibodies.

Nuclear extracts (5  $\mu$ g) from ND7/23 cells were incubated with double-stranded  $^{32}$ P-labeled oligonucleotides containing the P1b consensus CRE site (sense: 5'-CGCCGCCCCGTGACGTCAGAGCCCCCT-3'). In lane 1, no antibody was added. In lane  
30 2, a mouse monoclonal antibody (sc-270 Santa Cruz Biotechnology, Santa Cruz, CA) reactive with members of the ATF/CREB family such as ATF-1 p35, CREB-1 p43 and

CREM-1 was pre-incubated at room temperature for 20 min before addition of  $^{32}\text{P}$ -labeled probe. The specific complex between nuclear factors and the CRE is indicated by a star and the super-shifted complex is indicated by two stars.

## CLAIMS

1. A nucleic acid molecule constituting a human GABA<sub>B</sub> receptor 1 promoter P1a, or a functionally equivalent modified form thereof, or an active fragment thereof.  
5
2. A nucleic acid molecule according to claim 1 selected from:  
(a) a nucleic acid molecule comprising a nucleotide sequence set forth as SEQ ID NO: 1;  
(b) a nucleic acid molecule comprising a nucleotide sequence capable of hybridizing,  
10 under stringent conditions, to a nucleotide sequence complementary to the polypeptide coding region of a DNA molecule as defined in (a).
3. A nucleic acid molecule constituting a human GABA<sub>B</sub> receptor 1 promoter P1b, or a functionally equivalent modified form thereof, or an active fragment thereof.  
15
4. A nucleic acid molecule according to claim 1 selected from:  
(a) a nucleic acid molecule comprising a nucleotide sequence set forth as SEQ ID NO: 2;  
(b) a nucleic acid molecule comprising a nucleotide sequence capable of hybridizing,  
20 under stringent conditions, to a nucleotide sequence complementary to the polypeptide coding region of a DNA molecule as defined in (a).
5. A nucleic acid molecule comprising a nucleic acid molecule according to claim 1, in combination with a nucleic acid molecule according to claim 3.  
25
6. A nucleic acid molecule comprising a nucleic acid molecule according to claim 2, in combination with a nucleic acid molecule according to claim 4.
7. A vector transformed with a nucleic acid molecule according to any one of claims 1  
30 to 6.

8. A cultured cell host harboring a vector according to claim 7.
9. An expression system comprising a nucleic acid molecule constituting  
a human GABA<sub>B</sub> receptor 1 promoter P1a, or a functionally equivalent modified  
form thereof, or an active fragment thereof.  
5
10. An expression system according to claim 9, comprising a nucleic acid molecule  
selected from:  
(a) a nucleic acid molecule comprising a nucleotide sequence set forth as SEQ ID  
NO: 1;  
10  
(b) a nucleic acid molecule comprising a nucleotide sequence capable of hybridizing,  
under stringent conditions, to a nucleotide sequence complementary to the  
polypeptide coding region of a DNA molecule as defined in (a).
- 15 11. An expression system comprising a nucleic acid molecule constituting  
a human GABA<sub>B</sub> receptor 1 promoter P1b, or a functionally equivalent modified  
form thereof, or an active fragment thereof.
- 20 12. An expression system according to claim 11, comprising a nucleic acid molecule  
selected from:  
(a) a nucleic acid molecule comprising a nucleotide sequence set forth as SEQ ID  
NO: 2;  
(b) a nucleic acid molecule comprising a nucleotide sequence capable of hybridizing,  
under stringent conditions, to a nucleotide sequence complementary to the  
25 polypeptide coding region of a DNA molecule as defined in (a).
13. An expression system comprising a nucleic acid molecule according to claim 1, in  
combination with a nucleic acid molecule according to claim 3.
- 30 14. An expression system comprising a nucleic acid molecule according to claim 2, in  
combination with a nucleic acid molecule according to claim 4.

15. An expression system according to any one of claims 9 to 14, which, in addition, comprises a reporter gene.
- 5 16. An expression system according to claim 15, wherein the reporter gene is selected from:
- (a) the firefly luciferase gene,
  - (b) the bacterial amphenicol acetyl transferase (CAT) gene,
  - (c) the  $\beta$ -galactosidase ( $\beta$ -GAL) gene, and
  - 10 (d) the green fluorescent (GFP) gene.
17. An expression system according to claim 15 or claim 16, wherein the promoter and the reporter gene are positioned so that the expression system of the reporter gene is regulated by the GABA<sub>B</sub> receptor 1 promoter.
- 15 18. An expression system according to any one of claims 9 to 17, wherein the said nucleic acid molecule is transformed in a vector.
19. An expression system according to claim 18, wherein said vector comprises an origin of replication and/or a dominant selection marker.
- 20 20. A host cell transfected with an expression system according to any one of claims 9 to 19.
- 25 21. A method of assay for GABA<sub>B</sub> receptor promoter activity, comprising the use of a host cell according to claim 20.
22. A method for screening compounds which are modulators of GABA<sub>B</sub> receptor 1 transcription, comprising the steps of:
- 30 (a) transfecting a cell host with a suitable expression system comprising a nucleic acid molecule constituting a human GABA<sub>B</sub> receptor 1 promoter P1a, and/or a



human GABA<sub>B</sub> receptor 1 promoter P1b, or functionally equivalent modified forms, or active fragments thereof coupled to a reporter gene;

(b) contacting a test compound with the cell; and

(c) determining whether the test compound modulates the level of expression of the reporter gene.

23. A method according to claim 22, wherein the said expression system is an expression system according to any one of claims 9 to 19.

24. A method according to claim 22, wherein the said the reporter gene is selected from:

(a) the firefly luciferase gene,

(b) the bacterial amphenicol acetyl transferase (CAT) gene,

(c) the  $\beta$ -galactosidase ( $\beta$ -GAL) gene, and

(d) the green fluorescent (GFP) gene.

25. The method according to claim 22, wherein the host cell endogenously expresses GABA<sub>B</sub> receptor 1.


26. The method according to claim 22, wherein the host cell is further transfected with a suitable expression system comprising a nucleic acid molecule encoding one or more specific transcription factors.

27. The method according to claim 26, where the transcription factor is selected from the group: CREB-1, CREB-2, CREM-1, ATF-1, ATF-2, ATF-3, ATF-4, Sp1, Sp2, Sp3, Sp4, AP-1, and AP-2.

28. A transgenic non-human animal whose genome comprises an expression system comprising nucleic acid molecules constituting GABA<sub>B</sub> receptor promoters P1a and/or P1b, or functionally equivalent modified forms thereof, or active fragments thereof, coupled to a reporter gene.

29. A transgenic non-human animal whose genome comprises an expression system according to any one of claims 9 to 19.
- 5 30. A method for the screening of compounds which are modulators of GABA<sub>B</sub> receptor 1 transcription, comprising the use of a transgenic non-human animal according to claim 28 or claim 29.
- 10 31. A method for the screening of compounds which are modulators of GABA<sub>B</sub> receptor 1 transcription, comprising the use of tissues or cells isolated from a transgenic non-human animal according to claim 28 or claim 29.


Fig. 1



pAM 364

Fig. 2

### P1a (SEQ ID NO: 1)



### P1b (SEQ ID NO: 2)




Fig. 3






Fig. 4

Luciferase activity



P1a constructs



P1b constructs







Fig. 5

Luciferase activity



P1a constructs



P1b constructs





Fig. 6

Probe  
Supershift antibody

CRE  
- +



↑  
★ ★

↑  
★

↑  
Free Probe



## SEQUENCE LISTING

&lt;110&gt; AstraZeneca AB

&lt;120&gt; New methods

&lt;130&gt; H 2174-1 WO

&lt;140&gt;

&lt;141&gt;

&lt;160&gt; 2

&lt;170&gt; PatentIn Ver. 2.0

&lt;210&gt; 1

&lt;211&gt; 3903

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; GC\_signal

&lt;222&gt; Complement((3009)..(3016))

&lt;220&gt;

&lt;221&gt; GC\_signal

&lt;222&gt; (3037)..(3044)

&lt;220&gt;

&lt;221&gt; GC\_signal

&lt;222&gt; Complement((3116)..(3123))

&lt;220&gt;

&lt;221&gt; misc\_signal

&lt;222&gt; (1497)..(1503)

&lt;223&gt; PlA

&lt;400&gt; 1

```

gatcatatta atttgaaggt ggcggggcag gatggttctg tgggtgcagtt taagattaag 60
aggcatacac cacttagtaa actaatgaaa gcctattgtg aacgacaggg attgtcaatg 120
aggcagatca gattccgatt cgacgggcaa ccaatgaaac agacacacct gcacagttgg 180
aatggagga tgaagataca attgatgtgt tccaacagca gacgggaggt gtctactgaa 240
aagggaacct gcttctttac tccagaactc tggtctttta agaccaagat tacattctca 300
attagaaaac tgcaatttgc ttccaccaca tcttgactac taccgtatag ttttctctat 360
tctttcattt ccccttccc cattccttta ctgtacataa agtaactggt atatgtgcac 420
aagcatatta cttttttttt ttaaaactaa acagccaatg gtatgttttg attgacatca 480
agtggagacg ggggggaaaa tactgattct gtgaaaatac cccctttctc cattagtggc 540
atgctcattc agctcttacc tttatattcc agtaagttat tttgctctca ctgttttaac 600
aacaacaaca aaaaaacaac aacataaaaa tccttgcata ccttggtcaa ttggagaatt 660
ttaatgtttt tcatattatca ttgtaaaacc aaggacaatt ttataacttt tttgtactta 720
gctgttacat gcagagcaat ctgtctttta gtagggataa attactctaa aacaaaaaag 780
aatcctagat agttttccct tcaagtcaag cgtcttggtg tttaaataaa cttcttggtt 840
aaaaaaaaaa aaagtaaaaa agaaaagtta tgcaacaatt aatggcccag aggcaatcct 900
tgттаacatt ttgatgcac ttttagctgt tttttttttt tttttttttt ttgactgagt 960

```

ttgactcttg	tcaccagggc	tgaagtgc	tggcatggca	tgatcttggc	tcactgcaac	1020
ctccgcctcc	cgggttcaag	tgattctcct	gcctcagcct	cctgagtagc	taggattacg	1080
ggcatgcacc	accatgcctg	gctaattttg	tatttttagt	agagttgggg	cttctccaca	1140
ctggtcaggc	tggtctcgaa	ctcccaacct	cagggtgataa	gggaaggggc	actattgaca	1200
tttatgggtg	gggcagaggt	gtaagatatt	cttcaaagca	ctacctacat	gttgaagaat	1260
tgttccctac	ccagattctc	aaaagtcccc	caggacattc	acgtagtga	aacctgtgt	1320
taattatctg	agcctataac	ttaatacagt	ttcaaaattt	ttttttaaat	atacagtga	1380
ctttctagga	atgcaattat	agttgtgtgt	aaaattaggg	aaaattaact	ttgctaccaa	1440
gagttgttca	acattttgtt	aaatcacttc	attgatggca	acatgctgga	ggtagttgag	1500
tcaccaactc	agcacctgga	tcagcctgtg	ttggtagcag	tttcatcccc	gtggttctgt	1560
gaatagggtg	aagcatctgc	ttactccatc	aggacttcta	gggtagtcgg	gccttggcag	1620
tcacacatta	aaatactgtt	tatgttattt	tattgcaagt	tacttttctt	tcatttcccc	1680
tttacgttac	agaaagggaa	gcattttgct	ttctgtttta	agttgtgtat	gtaggtaggt	1740
tatatcatct	awgactttct	ctccctcctt	ccctttcttt	ttgtttgaga	tggagtcttg	1800
ctctgtcacc	caggctggag	tgcagtgggt	cgatcttggc	tcactgcaac	ctctgcctcc	1860
cgggttcaag	cgattctggg	gtctcagctg	ggattacagg	cgcacaccat	cacaccacgc	1920
taatttttct	attttttagt	gagatggggg	ttcgccatgc	tggccaggcc	aggctgggtc	1980
caaactcctg	agctcaagtg	atcagtccgc	ctcgccctcc	caaagtctctg	ggatttcagg	2040
cgtgagcctc	atctatgaat	ctcaatttag	gacagtaaaa	gtgtcattac	aaaaatattc	2100
attgtaaaaa	aggggttgag	gttgagaatc	tcaattctag	tcagtctctc	agtgtttggg	2160
ttcttctctc	catttttccc	cctaggacca	gccagaaagc	agcttttttt	ttgtccctcc	2220
caacaaggag	cccactgttt	cctctcccag	cccaaaactc	ggcctacgaa	caacaacagc	2280
actacacaca	cacacacaca	cacacacaca	cacacacaca	caccctccca	cttcaaggta	2340
tagccaagag	cttctggagc	cgtcaaaaag	gtctgtacct	gctgtcttta	gagcttccag	2400
tttgcccttg	gtcaagaaat	actgtttgct	aggctctgct	ggagtacatc	aggtaataat	2460
ggcttctaaa	ccaccctgag	gttcttttct	cttgtccttt	tactcccttc	gtacttcaat	2520
ttctctcctt	gatgtccccc	tccctgtttt	gtttttttgc	tccaatecgt	tctgcgcgtt	2580
ccctgcagag	caggcgagta	gcaatgctgc	tggaccatgg	agctgctcta	gtctcccaga	2640
aatctcttct	acaccaaac	cttcttgctc	ttagggtggtc	ctcagtcctc	ctccccacc	2700
tccttctgac	ccaggcttct	ttctcgcctt	ccggtcgcag	ttctcctggg	catctgcctc	2760
tgcctctctc	ctctcaccgc	gatctagggc	tgccttctct	ttgtgcagcc	gtctttctcc	2820
accttctatc	cagactccct	gtctcagcgc	cagctcctct	gcctttgggt	cgggttccct	2880
ctccccacc	ccagcttcca	gttgtttggc	ccgcagggtc	ctcggcagtg	accgcgcctc	2940
ccgcagagtg	gcgtgtgcac	cagggcacct	ccctctcccc	cacctctcag	ccccgcgcct	3000
ctccaccgct	cgccccaccg	cgctgtgggc	gggtccagggc	ggggctggga	tccggggcgg	3060
ctcccggggc	tccgggttgtg	ggaggcgccc	tctccccggg	cttccccctc	cttccccccg	3120
ccctgccttc	ccttgcaacc	tccttcttcc	ctccgcctcg	gagctctccc	tggtcccccg	3180
cgcgcctctc	ttccctcccc	gtcccccgct	ccccgctccc	gtggctgccg	ccgccccggg	3240
gaagaagaga	caggggtggg	gtttggggga	agcgagagag	gaggggagag	accttgcca	3300
ggctggagcc	tggattcgag	gggaggaggg	acgggaggag	gagaaagggtg	gaggagaagg	3360
gaggggggag	cggggaggag	cggccggggc	tggggccttg	aggcccgggg	agagccgggg	3420
agccggggcc	gcgcgccgag	gtaagagcca	gggccccggg	ttagcagggc	tcggagaggg	3480
ggcgcgccgc	gtgggtgggg	agggggcagt	gggcgcaggg	cccagctggg	ggaagcgggg	3540
ctgggggaga	ggaggaaccg	cggggatgga	atcggggagc	gctgagggcg	ccgatgccgg	3600
gagcgtgggt	aagccaggct	tctgcgagcc	gcggggggccg	ggggagagga	ggtggtgaga	3660
ggtggagtcc	gggagggttg	ggggccgagg	gaggcaggag	gaggggtggg	acaggctttc	3720
tctctctctc	tccccccacc	ccgcgcgggg	ctccgcccc	gcctcctccg	cggggcgctc	3780
tcttggtccc	caggctgagc	ccggctcgag	cctgcgaggg	aaccggcaag	aggtcgagta	3840
gtctccgggt	gcgggcccgc	ccggcggggc	tcggtccagt	cctcatggcc	gcctctcact	3900
tag						3903

<210> 2  
 <211> 4594  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> GC\_signal  
 <222> Complement((4080)..(4087))

<220>  
 <221> GC\_signal  
 <222> Complement((4196)..(4205))

<220>  
 <221> GC\_signal  
 <222> Complement((4241)..(4249))

<220>  
 <221> GC\_signal  
 <222> Complement((4272)..(4279))

<220>  
 <221> misc\_binding  
 <222> (3844)..(3851)  
 <223> AP-2

<220>  
 <221> misc\_binding  
 <222> (4308)..(4315)  
 <223> CRE

<220>  
 <221> misc\_binding  
 <222> (4375)..(4381)  
 <223> Initiator

<400> 2  
 atgttgctgc tgctgctact ggcgccactc ttctctccgcc ccccggggcgc gggcgggggcg 60  
 cagacccccca acgccacctc agaaggtgca tctttcttcg acgacctccg gccctccttc 120  
 gctccacttc cttttccctg catctctca tttctgggcc tcatcactat cccatcagtc 180  
 ccacatatca tcccggtctg gcaacccctt ctgctcggcc cgactttact actgctgacc 240  
 tccttctgtc accccacgtt actatccagc acctcttttc tctgcccaca ttgctacact 300  
 ataccacctt cctgtgcatt ttctccgcct caatccctt tcccagcccc acattactac 360  
 ctcaattact cctttttctt gggtccactt tgctgtccag atgatcttat tagcctccct 420  
 ttatcctcct atcctaattc aactggaata tcctcattta gccttttttt ttaaagaaaa 480  
 gctccaccca catatcatac cttcatgat ttcttaatta cttttctttc ttacctccac 540  
 ccagcacctt tccctcccca cttgtgggtt ctctcatcag ctttaaccct ggccctttac 600  
 tctctgtcct ttagccaggg gatctgtacc tgtccccact cccacctct agtgccccat 660  
 ccctcttctt ctgtccccag cctgcccaca gaccacgccc tactctcccc ttctctccac 720  
 tggggagcct gccttttctt ctttcccacc attcctctct gtatgcctcc ccgactcacc 780  
 ccttaggttg ccagatcata caccgcctt ggggaagggg catcaggtag cggggcctga 840  
 ctggggacca ggtgaaggct atcaacttcc tgccagtggc ctatgagatt gagtatgtgt 900  
 gccgggggga gcgcgagggt gtggggccca aggtccgcaa gtgcctggcc aacggctcct 960  
 ggacagatat ggacacaccc agccgctgtg gtgagtagcc tcggaagccc ctcccccttt 1020  
 caagactatt ctttttctg ccgcaaactt agcattactg cttgcaagtc agcactttaa 1080  
 atccagtata ccaaaattca caaatacatt tattgaatga ctactacata agagcaattt 1140  
 tgctctgtgc ggttgagggt agtagagcta gcagcctgca cagttcattt catcctccct 1200

tcattaggcc	actgatcatt	ggcctataac	attgataaatt	catcttgc	gttattctct	1260
ttgaggatca	ttagtggcag	atgatgacaa	aaaaattcta	aaatgatttc	atcacatttt	1320
tgaataacctc	tgccaccaac	ccagagacca	tatgcccag	aaacaaaagc	cagtttaata	1380
ttaatagaag	ccaactataa	taagaaaagc	aaatctgatt	gtgcatccaa	agttatatac	1440
atctacatat	ttcaaagcca	gagaaccgcc	cactgtagct	gactttgaag	agatcccatt	1500
ttgtgtgctt	atagcccat	cttgggttcc	taaaatggta	attttttttt	tcttttggga	1560
atgtgtggat	gcttgacag	gtaaggagg	attggaagat	aggtaggcaa	atccttttca	1620
catgtgattt	tcttttagagc	aggatgcttg	tggaccacaa	cctgcacctg	agtcctctgc	1680
tctttaaagg	gaaagagcct	tcttcaactc	gcctctcttc	ttatttttct	atctctccac	1740
agtccgaatc	tgctccaagt	cttatttgac	cctggaaaat	gggaagggtt	tcttgacggg	1800
tggggacctc	ccagctctgg	acggagcccc	gggtggatttc	cgggttgacc	ccgacttcca	1860
tctgggtggg	agctcccggg	gcatctgtag	tcaggggccag	tggagcacc	ccaagcccca	1920
ctgccagggt	gaggggaaca	gctgcctgca	tgcagctgat	gaggacgctt	gtgtgaggat	1980
gggagtgggg	tgggaatgga	taatgggaaa	gaatggagag	ctataaaaaat	gtggggggagg	2040
acactggaaa	ggggagatga	aagtcccttt	ttcctccatc	acctgcctca	aacttctctt	2100
tgcagtcctc	ggtatcctct	gtagggtggg	ggcttctctc	ctttaccttt	taaaaaaatc	2160
ttcctgctcc	cgattcttag	acctcacgtt	ttctcttttc	ctttatgaat	ctcacctctc	2220
tcaccttctt	caggtttaaa	tactccaatt	ttccctttct	ctaaacttag	aaatttccat	2280
gcatcacctc	cttctagaat	tcacccctca	ccattcctta	tataattgat	ttattgtaaa	2340
gactcagaaa	taaatacaac	attctactaa	gaaaaattga	gaaggggagc	tctgggggtg	2400
gaaacatatt	agggtaaaaag	acttaaaatt	ggaggcagca	ttatcagaag	atgaagaaca	2460
actcagggat	gggggtgggaa	gaagacaggt	ccttttctgk	acttcctaga	caacctccat	2520
tattccctaa	gggaatcagt	gttgtgtctg	tctacytttt	tttttttttt	tttgccacgt	2580
aattttacaa	actctccctt	ttctaggeac	ccgaactctc	tgccatcttc	tctcctggga	2640
tgcagtcctc	ccatttgtat	gcctcatact	tcctctaccc	tggtagattc	tttcaagatc	2700
cttgggcttt	actttcctca	cataactcag	ttattctgct	tctagtttac	cattttattc	2760
tggaaattga	gagtcccatc	caggggtgga	cttatgacac	tactgaaact	tagacttcaa	2820
ggttctctac	ctacagggcc	ctcttctctg	gctctaataa	tatagagggc	tcgatggata	2880
tgtttacata	tggtaacagg	cttttgtaaa	aattgcagaa	ataagatttt	aacagcaatt	2940
gcttaaacgc	aattgtatgt	gtaatttttt	ttcttaaaag	ctcccaattt	tgtataattc	3000
aggcaccaca	gaaccaagat	ctgccccaaa	cttagctatt	ggcattcccc	tctcaaatcc	3060
tgttgtccta	tgaaaaaatcg	aagaagaaaa	taagtccctga	cccccttacc	cccagaccca	3120
ccttgttctt	atccccaggc	accctccctt	cagaaacgca	ggcttctgct	ctccccgggc	3180
ttcagcatgg	acagggtgtg	gagggggctg	gggatcaggc	caggggaagc	gggcgccagt	3240
ggtaactctt	ctctgatccc	cgtctttctt	gctgccagtg	aatcgaacgc	cacactcagg	3300
tgagatgaga	aacctttacc	gcgcgcactg	caatgccctc	cccttcactc	tgcacctctc	3360
acccccctga	aattctgccc	ttaggctacg	gggcgtcgtc	ctttcgcacc	ttccccaaac	3420
cacccccagt	tgcggccacc	cccttccctc	cctacctgtt	tcttgcctcc	agtcctgggt	3480
ttccacgagg	ctgcggtctc	tccttgctcc	tgtttggcta	cacttccctg	ggctccacct	3540
cctcccagac	tgagcctcgc	cgggtgtcagg	cagagcccag	cagarggcgg	caggggtgctg	3600
ggagaccctg	agctcccacc	acgttttccc	ctgtgggggt	ccttgcgacc	ttcgtcggaa	3660
ccttttccag	cctgctgcct	cctaggattt	cacctaatgg	actttctcag	cctgtcccac	3720
ccatcccaac	cctggccagg	cctctcgcgc	tcttccccac	atcttttctt	tccgtgtacc	3780
ccttccctcg	tctttttctca	atcccatgtc	ctgtctccct	ttcttaggct	tctgtctacc	3840
cagccccagg	ctcccttcca	cgacccccac	actccctcaa	accagcctcc	cttccgtacc	3900
caactcgttc	cctccaaaac	cgtttctctt	ccccacatc	ctcagtgttt	caactgtatc	3960
actcatactc	ccacttcaga	cctcaggcgc	cagccccgtt	tctctcccgt	cccactcgca	4020
tccttccctt	cctaccctgg	ttcctccgtg	cttcagcctc	ccgcggctcc	ctccgccccac	4080
cccgcctctc	tggcacgccc	cgtccccatt	tctcctcccc	tgggttcccc	ttaaagtgaga	4140
tccttccctt	cctctttctg	tcctttctct	ctcgagggtg	catccccctt	ccctcccccg	4200
cccctccgac	tgtcgtctcc	acctcggcgc	tcgtctccct	ccccgcccc	ttcttgcctc	4260
cccagctccc	gcccgcctcc	ccaccccccg	cgcgcgcgcg	cctccctctc	ctcagagacc	4320
ccctccagc	cccacatctc	cctcctgctc	ctcctctctc	cctccgtcgg	tcagtcagtc	4380
cgcgaggaga	gtccgcggtg	gcggcgacgg	tggcgagagc	cgcggggggc	gtaggaagcc	4440
aaccttccct	gcttctccgg	ggccctcgc	ccctcctccc	cacaaaatca	gggatggagg	4500
cgcctccccg	gcacctctt	agcagccctc	cccgggaaaa	gtgtcccccc	tgagctccta	4560
acgtccccca	acagctaccc	ctgcccccca	cggc			4594